Skip to main content

Table 2 Univariate Cox regression analysis of KLK12 mRNA expression in relation to patients’ outcome in triple-negative breast cancer

From: Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients

Clinical parameters

OS

DFS

No.a

HR (95% CI)b

p

No.a

HR (95% CI)b

p

Age

  

<  0.001

  

0.001

 ≤ 60 years

67

1

 

67

1

 

 > 60 years

58

2.96 (1.63–5.36)

 

56

2.45 (1.42–4.23)

 

Lymph node status

  

0.055

  

0.118

 N0

70

1

 

69

1

 

 N1/N2/N3

55

1.74 (0.99–3.07)

 

54

1.53 (0.90–2.59)

 

Tumor size

  

0.117

  

0.204

 ≤ 20 mm

33

1

 

33

1

 

 > 20 mm

91

1.83 (0.86–3.92)

 

89

1.54 (0.79–2.98)

 

Histological grade

  

0.915

  

0.600

 II

21

1

 

21

1

 

 III

104

1.04 (0.49–2.23)

 

102

1.22 (0.58–2.59)

 

KLK12 mRNAc

  

0.037

  

0.010

 Negative

61

1

 

59

1

 

 Positive

54

1.91 (1.04–3.50)

 

54

2.12 (1.19–3.78)

 

KLK12 mRNA posd

  

0.047

  

0.051

 Low

16

1

 

16

1

 

 High

38

2.98 (1.02–8.74)

 

38

2.64 (1.00–6.96)

 
  1. Significant p-values (p ≤ 0.05) are indicated in bold, trends towards significance (p ≤ 0.06) in italics
  2. Due to missing values, numbers do not always add up to n = 125 (OS) and n = 123 (DFS), when the whole cohort is analyzed
  3. a Number of patients
  4. bHR Hazard ratio (CI Confidence interval) of univariate Cox regression analysis
  5. c Dichotomized into positive and negative expression
  6. d Positive KLK12 mRNA values were dichotomized into low and high expression by the 30th percentile